| Market Cap | 14.65B | P/E | 45.93 | EPS this Y | 27.30% | Ern Qtrly Grth | 606.50% |
| Income | 597.6M | Forward P/E | 14.31 | EPS next Y | 18.50% | 50D Avg Chg | 5.00% |
| Sales | 3.7B | PEG | 0.51 | EPS past 5Y | 4.86% | 200D Avg Chg | -10.00% |
| Dividend | N/A | Price/Book | 3.09 | EPS next 5Y | 22.50% | 52W High Chg | -24.00% |
| Recommedations | 2.20 | Quick Ratio | 3.55 | Shares Outstanding | 224.53M | 52W Low Chg | 8.00% |
| Insider Own | 1.58% | ROA | 6.46% | Shares Float | 186.98M | Beta | 0.67 |
| Inst Own | 100.00% | ROE | 12.50% | Shares Shorted/Prior | 8.27M/7.91M | Price | 65.68 |
| Gross Margin | 49.00% | Profit Margin | 16.17% | Avg. Volume | 1,913,524 | Target Price | 74.29 |
| Oper. Margin | 20.03% | Earnings Date | Apr 30 | Volume | 2,041,095 | Change | 3.12% |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
| Oppenheimer | Outperform | Apr 24, 24 |
| Cantor Fitzgerald | Neutral | Apr 23, 24 |
| RBC Capital | Sector Perform | Mar 25, 24 |
| B of A Securities | Neutral | Mar 13, 24 |
| Stifel | Hold | Mar 12, 24 |
| RBC Capital | Sector Perform | Mar 12, 24 |
| Jefferies | Buy | Feb 23, 24 |
| JMP Securities | Market Perform | Feb 14, 24 |
| BMO Capital | Market Perform | Feb 14, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Stein Steven H | EVP & Chief Medical.. EVP & Chief Medical Officer | Jan 03 | Sell | 65.51 | 7,365 | 482,481 | 90,218 | 01/05/24 |
| Tray Thomas | Principal Accounting.. Principal Accounting Officer | Dec 12 | Sell | 59.87 | 1,277 | 76,454 | 23,436 | 12/14/23 |
| Stein Steven H | EVP & Chief Medical.. EVP & Chief Medical Officer | Aug 01 | Sell | 63.28 | 21,511 | 1,361,216 | 97,583 | 08/03/23 |
| Tray Thomas | Principal Accounting.. Principal Accounting Officer | Jul 22 | Sell | 83.13 | 1,564 | 130,015 | 17,702 | 07/26/22 |
| Flannelly Barry P | EVP & General Manage.. EVP & General Manager US | Apr 08 | Option | 70.45 | 41,864 | 2,949,319 | 88,640 | 04/12/22 |
| Flannelly Barry P | EVP & General Manage.. EVP & General Manager US | Apr 08 | Sell | 83.23 | 43,993 | 3,661,537 | 65,163 | 04/12/22 |
| BAKER BROS. ADVISORS LP | Director Director | Mar 08 | Option | 22.05 | 40,000 | 882,000 | 33,059,604 | 03/10/22 |
| BAKER BROS. ADVISORS LP | Director Director | Mar 08 | Buy | 71.91 | 389,080 | 27,978,743 | 33,419,055 | 03/10/22 |
| BAKER BROS. ADVISORS LP | Director Director | Feb 17 | Buy | 68.11 | 525,804 | 35,812,510 | 33,039,604 | 02/22/22 |
| SWAIN PAULA J | EVP, Human Resources EVP, Human Resources | Jan 07 | Sell | 73.31 | 10,870 | 796,880 | 72,371 | 01/11/22 |
| SWAIN PAULA J | EVP, Human Resources EVP, Human Resources | Jan 07 | Option | 73.21 | 10,870 | 795,793 | 83,241 | 01/11/22 |
| BAKER BROS. ADVISORS LP | Director Director | Dec 15 | Buy | 70.89 | 1,595,519 | 113,106,342 | 30,932,696 | 12/17/21 |
| Wenqing Yao | EVP, Head of Discove.. EVP, Head of Discovery Chem | Jan 27 | Option | 73.21 | 21,545 | 1,577,309 | 163,770 | 01/27/21 |
| Wenqing Yao | EVP, Head of Discove.. EVP, Head of Discovery Chem | Jan 27 | Sell | 100 | 21,545 | 2,154,500 | 143,784 | 01/27/21 |
| Stein Steven H | EVP & Chief Medical.. EVP & Chief Medical Officer | Jan 27 | Option | 68.62 | 3,795 | 260,413 | 123,539 | 01/27/21 |
| Stein Steven H | EVP & Chief Medical.. EVP & Chief Medical Officer | Jan 27 | Sell | 100 | 3,795 | 379,500 | 119,744 | 01/27/21 |
| Iyengar Vijay K | EVP GPS, BD, & Licen.. EVP GPS, BD, & Licensing | Jan 27 | Option | 72.86 | 4,116 | 299,892 | 31,274 | 01/27/21 |
| Iyengar Vijay K | EVP GPS, BD, & Licen.. EVP GPS, BD, & Licensing | Jan 27 | Sell | 99 | 5,116 | 506,484 | 26,158 | 01/27/21 |
| Pasquale Maria E | EVP & General Counse.. EVP & General Counsel | Oct 13 | Option | 66.99 | 1,551 | 103,901 | 28,459 | 10/13/20 |
| Pasquale Maria E | EVP & General Counse.. EVP & General Counsel | Oct 13 | Sell | 95 | 1,423 | 135,185 | 28,331 | 10/13/20 |